UNSPSC 51332873: Propiomazine maleate

This classification denotes an antipsychotic agent C20H24N2OS.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OEY0ZC43SA, chemically known as 1-propanone, 1-(10-(2-(dimethylamino)propyl)-10h-phenothiazin-2-yl)-, (+/-), (2z)-2-butenedioate (1:1), but more generally known as propiomazine maleate, which bears US NIH Compound Identifier 5702109. European Medicines Agency schedules Propiomazine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04084MIG.

Most nations, for tariff and trade purposes, schedule propiomazine maleate under HS 29343090 and SITC 51578. As of Q4 2014, PROPIOMAZINE MALEATE remains US FDA's Preferred Term for this commodity. SMILES: CCC(=O)C1CCC2C(C1)N(C3CCCCC3S2)CC(C)N(C)C.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51332873 Propiomazine maleate, a Commodity code, shows limited recent state and local procurement activity directly aligned with this specific pharmaceutical ingredient. The three recent opportunities posted under this code involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals distribution—none of which explicitly target propiomazine maleate by name. State and local governments are soliciting pharmaceutical products and systems through health departments, multistate cooperative purchasing vehicles, and pharmacy benefit initiatives, but the coded opportunities do not reflect demand for this specific active pharmaceutical ingredient as a standalone procurement item. The work being solicited includes annual naloxone and drug deactivation system procurement, market intelligence gathering on direct pharmacy contracting models, and master supply agreements for generic drugs through authorized wholesalers.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB60459723LAS in June 2026 seeking 1,900 units of naloxone annually with a response deadline of July 26, 2023 (note: date discrepancy in source), procuring through its county purchasing office with quarterly deliveries required. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor information on direct-to-manufacturer prescription fulfillment models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, serving state and local facilities across multiple states. The code shows no standout repeat buyers for propiomazine maleate specifically, and the recent opportunities suggest that state and local procurement under this code focuses on broader pharmaceutical supply and drug-safety initiatives rather than this particular ingredient in isolation.